Use of Multiphoton Microscopy in the Diagnosis of Cancer

Prostate Cancer Clinical Trial

— MPM  

Official title:

Use of Multiphoton Microscopy in the Diagnosis of Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00652210
• Other study ID #: 0506007919
• Status: Completed
• Phase: Phase 1
• First received: March 31, 2008
• Last updated: December 8, 2015
• Start date: June 2005
• Est. completion date: September 2015

Study information

• Verified date: December 2015
• Source: Weill Medical College of Cornell University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Multiphoton microscopy (MPM) has been shown to be able to image tissue at a cellular level. Our project will initially evaluated the ability of MPM imaging to distinguish normal bladder urothelium from atypical and malignant urothelium in the ex vivo setting. After development of sufficient criteria, we plan to develop an endoscopic bladder probe that will provide a non-invasive means to image the interior of the bladder at the cellular level, which would provide direct evidence of the presence of tumor without a biopsy. After exhibiting usefulness of MPM imaging for bladder cancer, we will look at other organs beginning with the colon.

Description:

Same as above

Recruitment information / eligibility

• Status: Completed
• Enrollment: 344
• Est. completion date: September 2015
• Est. primary completion date: September 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 21 Years to 85 Years

Eligibility

Inclusion Criteria:

• Anyone who presents with bladder and/or prostate cancer

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Bladder Cancer
• Prostate Cancer
• Prostatic Neoplasms
• Urinary Bladder Neoplasms

Intervention

Other:
• Multiphoton microscopy
Use of multiphoton microscopy to diagnose cancer

Locations

Country	Name	City	State
United States	Weill Cornell Medical College	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Weill Medical College of Cornell University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	After several delays, the multiphoton microscope has been delivered to Weill Cornell Medical College. We have been using this time to set-up and fine tune the multiphoton microscope. As of current, no negative events have occurred.		10/14/2007 to 2/15/2008	No